Suicidal Ideation and BehaviorATTAQNCT07430566
Trauma Exposure and Suicidal Behaviors in Adolescents Aged 11-17 Hospitalized in Child and Adolescent Psychiatry
A study testing Blood samples, genetic analysis and Questionnaires and scales in people with Suicidal Ideation and Behavior and Psychiatric Hospitalization, run by University Hospital, Montpellier.
Trial summary
It is a comparative monocentric study with longitudinal follow-up at 6 months in adolescents aged between 11 years and 17 years inclusive admitted to complete hospitalization either for suicidal behaviors or for other psychiatric causes. Read more about this study
- Who is it for?
- Ages 11 to 17 years
- Conditions the study is for
- Suicidal Ideation and Behavior, Psychiatric Hospitalization
- What is being tested?
- Blood samples, genetic analysis and Questionnaires and scales
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- No sites listed yet
- Study dates
- Mar 2026to Sep 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 11 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Reason for admission: suicidal behavior (suicide attempt)
- Reason for admission: other psychiatric causes (including suicidal thoughts without suicide attempt and non-suicidal self-injurious behavior)
- Common Exclusion Criteria:
- Neither parent available to participate in the intervention
Who cannot join
- History of suicidal behavior prior to the current hospitalization
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
It is a comparative monocentric study with longitudinal follow-up at 6 months in adolescents aged between 11 years and 17 years inclusive admitted to complete hospitalization either for suicidal behaviors or for other psychiatric causes. The objective is to explore the experiences of hospitalized adolescents regarding hospitalization, as well as their perceptions of the factors involved in their remission and their experience of the traumatic event(s) if they have been exposed.
Read the detailed description
Suicidal behaviors among adolescents are a major public health issue. Traumatic exposure (sexual abuse, violence, serious accidents) is a recognized risk factor for psychopathology and suicidality, but its precise links with suicide recurrence, comorbid psychopathology, and neurodevelopmental vulnerability remain little studied.
Hypotheses:
- Traumatic exposure is more common among suicidal adolescents than non-suicidal.
- It is associated with an increased risk of recurrence within 6 months.
- The neurodevelopmental load, irritability, PTSD and lack of resilience factors modulate this risk.
- Specific inflammatory biological profiles could be associated with suicidality.
Originality and innovative aspects:
- Multidimensional approach: clinical, psychometric, biological and qualitative.
- Constitution of a biobank for future analyses (inflammatory, genetic, epigenetic).
- Inclusion of a qualitative component exploring the subjective experience of hospitalized adolescents.
- Integrated analysis of risk, protective and biological factors to guide personalized prevention.
The main objective is to compare the frequency of traumatic exposure history evaluated with the validated questionnaire in French of the CPC version child, among adolescents aged between 11 years old and 17 years inclusive admitted to hospital, either for suicidal behaviors (suicide group), either for other psychiatric causes without a history of suicidal behavior (non-suicidal group).
- Being tested
- Blood samples, genetic analysis, Questionnaires and scales
- Keywords
- suicide, adolescent, post-traumatic stress disorder, neurodevelopmental disorders, résilience, biomarqueurs, comportements suicidaires
- Medical subject headings
- Suicidal Ideation, Behavior, Suicide, Stress Disorders, Post-Traumatic, Neurodevelopmental Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood samplesBiological
A blood test will be carried out during the inclusion visit, on site, with collection of the time of completion, the last food samples and tobacco consumption. A 2.5 mL Paxgene® tube for whole blood RNA and a 5 mL dry tube for serum will be collected.
genetic analysisGenetic
If consent for genetic analyses is obtained, a 4.5 mL EDTA tube to collect native DNA will be taken during the blood test
Questionnaires and scalesOther
- Child Posttraumatic Checklist (CPC)
- Life Event Checklist (LEC-5)
- Posttraumatic CheckList-5
- K-SADS
- Affective Reactivity Index (ARI)
- Child Youth Resilience Measure
- Adverse Childhood Experiences International Questionnaire (ACE-IQ)
- Metacognitions Questionnaire (MCQ-A)
- Cognitive Emotion Regulation Questionnaire (CERQ)
- Adolescent Dissociative Experience Scale (A-DES)
- Behavioral Rating Inventory of Executive Function Self-Report (BRIEF-2)
| Study group | Role | What they receive |
|---|---|---|
| suicide group | Active comparator | adolescents aged between 11 years old and 17 years inclusive admitted to hospital for suicidal behaviors Receives: Biological: Blood samples; Genetic: genetic analysis; Other: Questionnaires and scales |
| non-suicidal group | Active comparator | aged between 11 years old and 17 years inclusive admitted to hospital for other psychiatric causes without a history of suicidal behavior Receives: Biological: Blood samples; Genetic: genetic analysis; Other: Questionnaires and scales |
What is being measured
The primary outcome is the main question the study is designed to answer.
CPC Questionnaire child version
This questionnaire evaluates the symptoms of PTSD and their frequency in children aged 7 to 18 years, following a traumatic event. Completion time is 15-20 minutes and the total score can range from 0 (no symptoms) to 84 (maximum symptoms) for symptom intensity and from 0 (no functional impact) to 24 (maximum functional impact) for functional impairment. The scale will be administered by a clinician (psychologist or psychiatrist for children and adolescents).
Measured: Baseline
Secondary outcomes (17)
CPC questionnaire parents version
This questionnaire evaluates by parents the symptoms of their children in PTSD and their frequency in children aged 7 to 18 years, following a traumatic event. Completion time is 15-20 minutes and the total score can range from 0 (no symptoms) to 84 (maximum symptoms) for symptom intensity and from 0 (no functional impact) to 24 (maximum functional impact) for functional impairment. The scale will be administered by a clinician or self-administered (psychologist or psychiatrist for children and adolescents).
Measured: Baseline
Questionnaire Life Event Checklist (LEC-5)
The Life Event Checklist version of DSM-5 (19) consists of a list of 16 potentially trauma events in reference to criterion 1 of PTSD from DSM-5. It does not generate a total score but allows for a record of trauma events if they have occurred or not.
Measured: Baseline
Schedule for Affective Disorders and Schizophrenia for school-age children (KSADS) full-life version
It is a hetero-administered questionnaire that allows for the screening and diagnosis of psychiatric and neurodevelopmental disorders in children and adolescents.
Measured: Baseline
Post-traumatic Stress Disorder Checklist for DSM-5 (PCL-5)
The PCL-5 (23) is composed of 20 items that correspond to the 20 PTSD criteria detailed in the DSM-5, and contains four subscales corresponding to the four clusters of symptoms in the DSM-5: intrusion phenomena, avoidance, negative alterations of cognition and mood, and increase in hyperactivity and reactivity. The score can range from 0 (no symptoms) to 80 (maximum symptoms). PCL-5 is a self-administered questionnaire that can also be administered with the help of a clinician.
Measured: Baseline
Affective Reactivity Index (ARI)
It is a clinician administered semi-structured scale designed to measure pediatric irritability
Measured: Baseline
Child Youth Resilience Measure (CYRM)
The CHYRM (26) is a scale used to measure social and family support and child skills. The child version is in two versions: one for 7-10 years old and one for 11-18 years old. There is also a version to be completed by the parents on their perception of social and family support and skills of the child (one for 7-10 years old and one for 11-18 years old).
Measured: Baseline
Adverse Childhood Experiences International Questionnaire (ACE-IQ)
The ACE-IQ evaluates childhood adverse experiences into 29 items and 13 categories of traumatic experiences experienced during childhood.
Measured: Baseline
CER-Q
the CERQ is a self-administered questionnaire which identifies 9 cognitive strategies of emotional regulation into 36 items
Measured: Baseline
BRIEF-2
The BRIEF-2 is a scale assessing daily behaviors at school and home, related to the executive functions of children between 5 and 17 years. The self-reported questionnaire takes about 10 minutes to complete.
Measured: Baseline
Meta-Cognitions Questionnaire for Adolescents (MCQ-A)
This tool consisting of 30 items highlights five sub-dimensions of metacognition: excessive monitoring, non-trust in one's memory, negative metacognitive beliefs related to superstition, negative and positive metacognitive beliefs.
Measured: Baseline
DES-A
The DES-A is a self-reported questionnaire in 30 items allowing to detect different dissociative phenomena in teenagers between 11 and 17 years old. A total score corresponding to the severity of dissociative behaviors is obtained by adding the scores of each item.The minimum score is 1 and the maximum 10.
Measured: Baseline
Neurodevelopmental score
Neurodevelopmental burden calculated using the neurodevelopmental score: maternal age, paternal age, presence of ADHD, specific learning disorders, bipolar disorder before age 15, eating disorder (ED) before age 15, anxiety disorder before age 15, substance use disorder (SUD) before age 15, traumatic exposure. ADHD, specific learning disorders, bipolar disorder, ED, anxiety disorder, and SUD are diagnosed using the K-SADS.
Measured: Baseline
Screen time
Defined as the time spent per day on a screen (phone, tablet, computer, television), outside of school hours, during weekends, holidays, and public holidays.
Measured: Baseline
Perinatal history : parental psychiatric disorders
Measured: Baseline
Perinatal history : parental age at birth
Measured: Baseline
Perinatal history : perinatal complications
Measured: Baseline
Collection of suicidal behavior
Direct questioning on the occurrence of suicidal behaviors since the last evaluation, verification of medical records (subsequent admissions to psychiatry for suicide attempt).
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Feb 2026
- Study startMar 2026 (estimated)
- Primary completionMar 2027 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Suicidal Ideation and BehaviorStudies of the same condition, open and under way.
- More trials run by University Hospital, MontpellierThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Comparative study, monocentric, longitudinal, with follow-up at 6 months
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Montpellier
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07430566
- Sponsor's protocol ID
- RECHMPL25_0312
- Other IDs
- 2025-A02017-42
- Acronym
- ATTAQ
- Status last verified
- Feb 2026
- First submitted
- 18 Feb 2026
- Last updated
- 24 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Trauma Exposure and Suicidal Behaviors in Adolescents Aged 11-17 Hospitalized in Child and Adolescent Psychiatry
- ClinicalTrials.gov ID
- NCT07430566
- Acronym / sponsor ID
- ATTAQ / RECHMPL25_0312
- Keywords
- suicide, adolescent, post-traumatic stress disorder, neurodevelopmental disorders, résilience, biomarqueurs, comportements suicidaires
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- University Hospital, MontpellierUniversity, hospital or other
- Study start
- Mar 2026 (estimated)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Sep 2027 (estimated)
- First posted
- 24 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is a comparative monocentric study with longitudinal follow-up at 6 months in adolescents aged between 11 years and 17 years inclusive admitted to complete hospitalization either for suicidal behaviors or for other psychiatric causes. The objective is to explore the experiences of hospitalized adolescents regarding hospitalization, as well as their perceptions of the factors involved in their remission and their experience of the traumatic event(s) if they have been exposed.
Detailed description
Suicidal behaviors among adolescents are a major public health issue. Traumatic exposure (sexual abuse, violence, serious accidents) is a recognized risk factor for psychopathology and suicidality, but its precise links with suicide recurrence, comorbid psychopathology, and neurodevelopmental vulnerability remain little studied.
Hypotheses:
- Traumatic exposure is more common among suicidal adolescents than non-suicidal.
- It is associated with an increased risk of recurrence within 6 months.
- The neurodevelopmental load, irritability, PTSD and lack of resilience factors modulate this risk.
- Specific inflammatory biological profiles could be associated with suicidality.
Originality and innovative aspects:
- Multidimensional approach: clinical, psychometric, biological and qualitative.
- Constitution of a biobank for future analyses (inflammatory, genetic, epigenetic).
- Inclusion of a qualitative component exploring the subjective experience of hospitalized adolescents.
- Integrated analysis of risk, protective and biological factors to guide personalized prevention.
The main objective is to compare the frequency of traumatic exposure history evaluated with the validated questionnaire in French of the CPC version child, among adolescents aged between 11 years old and 17 years inclusive admitted to hospital, either for suicidal behaviors (suicide group), either for other psychiatric causes without a history of suicidal behavior (non-suicidal group).
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Comparative study, monocentric, longitudinal, with follow-up at 6 months
| Arm | Type | Receives |
|---|---|---|
| suicide group | Active comparator | Biological: Blood samples, Genetic: genetic analysis, Other: Questionnaires and scalesadolescents aged between 11 years old and 17 years inclusive admitted to hospital for suicidal behaviors |
| non-suicidal group | Active comparator | Biological: Blood samples, Genetic: genetic analysis, Other: Questionnaires and scalesaged between 11 years old and 17 years inclusive admitted to hospital for other psychiatric causes without a history of suicidal behavior |
Who may qualify
- Ages
- 11 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Reason for admission: suicidal behavior (suicide attempt)
- Reason for admission: other psychiatric causes (including suicidal thoughts without suicide attempt and non-suicidal self-injurious behavior)
- Neither parent available to participate in the intervention
Key exclusion criteria (1 listed)
- History of suicidal behavior prior to the current hospitalization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood samplesA blood test will be carried out during the inclusion visit, on site, with collection of the time of completion, the last food samples and tobacco consumption. A 2.5 mL Paxgene® tube for whole blood RNA and a 5 mL dry tube for serum will be collected. | Biological | non-suicidal group, suicide group |
| genetic analysisIf consent for genetic analyses is obtained, a 4.5 mL EDTA tube to collect native DNA will be taken during the blood test | Genetic | non-suicidal group, suicide group |
| Questionnaires and scales* Child Posttraumatic Checklist (CPC) * Life Event Checklist (LEC-5) * Posttraumatic CheckList-5 * K-SADS * Affective Reactivity Index (ARI) * Child Youth Resilience Measure * Adverse Childhood Experiences International Questionnaire (ACE-IQ) * Metacognitions Questionnaire (MCQ-A) * Cognitive Emotion Regulation Questionnaire (CERQ) * Adolescent Dissociative Experience Scale (A-DES) * Behavioral Rating Inventory of Executive Function Self-Report (BRIEF-2) | Other | non-suicidal group, suicide group |
Primary outcome
CPC Questionnaire child version
Time frame: Baseline
This questionnaire evaluates the symptoms of PTSD and their frequency in children aged 7 to 18 years, following a traumatic event. Completion time is 15-20 minutes and the total score can range from 0 (no symptoms) to 84 (maximum symptoms) for symptom intensity and from 0 (no functional impact) to 24 (maximum functional impact) for functional impairment. The scale will be administered by a clinician (psychologist or psychiatrist for children and adolescents).
17 secondary outcomes
CPC questionnaire parents version
Time frame: Baseline
Questionnaire Life Event Checklist (LEC-5)
Time frame: Baseline
Schedule for Affective Disorders and Schizophrenia for school-age children (KSADS) full-life version
Time frame: Baseline
Post-traumatic Stress Disorder Checklist for DSM-5 (PCL-5)
Time frame: Baseline
Affective Reactivity Index (ARI)
Time frame: Baseline
Child Youth Resilience Measure (CYRM)
Time frame: Baseline
Adverse Childhood Experiences International Questionnaire (ACE-IQ)
Time frame: Baseline
CER-Q
Time frame: Baseline
BRIEF-2
Time frame: Baseline
Meta-Cognitions Questionnaire for Adolescents (MCQ-A)
Time frame: Baseline
DES-A
Time frame: Baseline
Neurodevelopmental score
Time frame: Baseline
Screen time
Time frame: Baseline
Perinatal history : parental psychiatric disorders
Time frame: Baseline
Perinatal history : parental age at birth
Time frame: Baseline
Perinatal history : perinatal complications
Time frame: Baseline
Collection of suicidal behavior
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2026.
Related trials for Suicidal Ideation and Behavior
RecruitingObservational study
Student Precarity and Psychiatry
Depressive Disorder, Major, Generalized Anxiety Disorder
Not yet recruiting
A MRT to Optimize a JITAI for Alcohol Craving and Suicide Ideation
Alcohol Use Disorder (AUD), Suicide Ideation
Not yet recruiting
Examining the Relationship Between Ongoing Alcohol Use, Suicidal Thoughts and Behaviors and Related Constructs, and Behavioral Economic Decision-Making.
Alcohol Use Disorder (AUD), Suicidal Ideation
Recruiting
Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings
Suicide, Attempted, Suicide Ideation
Active, not recruiting
Clinical Trial for Integrated Care to Help At Risk Teens (iCHART) Intervention
Suicide and Depression, Adolescent Behavior
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Blood samples, genetic analysis and Questionnaires and scales in people with Suicidal Ideation and Behavior and Psychiatric Hospitalization, run by University Hospital, Montpellier.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 24 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hala KERBAGE (0601819449 ext. +33, hala.kerbage@chu-montpellier.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CPC Questionnaire child version (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2026.